



PERSONAL INFORMATION

Name IDA MINCHELLA
Address SPORTING MIRASOLE STREET 48, 20090 NOVERASCO (MI)

E-mail ida.minchella@ieo.it

Nazionality Italian
Date / place of birth 02/01/1968 FORMIA (LT)

WORK EXPERIENCE

- Date (from – to) 04/2013 – today
- Employer name and address European Institute of Oncology Ripamonti Street Milan
- Position Deputy Director of the Division of Early Drug Development for Innovative Therapies
- Main activities and responsibilities Care and responsibilities of inpatients, outpatients and emergency. Co-investigator in phase I and II studies on solid tumors .
Clinical Auditor in the field of quality
- Date (from – to) 06/2010-03/2013
- Employer name and address European Institute of Oncology Ripamonti street 435 Milan
- Position Deputy Director of Medical Care Unit of Medical Oncology Division
- Main activities and responsibilities Care and responsibilities of outpatients with particular interest for the treatment of breast cancer.
Co-investigator of studies on breast cancer
Clinical Auditor in the field of quality and quality referent
- Date (from – to) 01/2003-05/2010
- Employer name and address European Institute of Oncology Ripamonti street 435 Milan
- Position Senior Assistant of Medical Care Unit of Medical Oncology Division
- Main activities and responsibilities Care and responsibilities of inpatients and outpatients with particular interest for the treatment of breast cancer and melanoma. Co-investigator of studies in breast cancer and metastatic melanoma. Quality referent
- Date (from – to) 01/2000-12/2002
- Employer name and address European Institute of Oncology Ripamonti street 435 Milan
- Position Assistant of Day Hospital with permanent contract
- Main activities and responsibilities Care and responsibilities of outpatients with particular interest for the treatment of breast cancer. Co-investigator of studies in breast cancer.
Quality referent

• Date (from – to)	18/03/99-12/99
• Employer name and address	European Institute of Oncology Ripamonti street 435 Milan
• Position	Assistant in Day Hospital with fixed-term contract
• Main activities and responsibilities	Outpatients Care. Co-investigator of studies in breast cancer
• Date (from – to)	01/1998-17/03/99
• Employer name and address	European Institute of Oncology Ripamonti street 435 Milan
• Position	Medical fellow
• Main activities and responsibilities	Outpatients care. Co- investigator for studies in breast cancer.
• Date (from – to)	09/1996-12/1997
• Employer name and address	European Institute of Oncology Ripamonti street 435 Milan
• Position	Medical internship
• Main activities and responsibilities	Outpatients and inpatients care
• Date (from –to)	1994-1996
• Employer name and address	University of Rome Tor Vergata
• Position	Medical internship
• Main activities and responsibilities	Research activities in the Unit directed by Chiara D'Onofrio for VII-VIII-IX AIDS Project, Ministry of Health/National Institute of Health, Rome
• Date (from – to)	1993-1994
• Employer name and address	Medical Oncology Department Celio Military Hospital Celimontana, square 50 - 00184 Rome
• Position	Medical internship
• Main activities and responsibilities	Outpatients and inpatients care

EDUCATION AND TRAINING

• Date (from – to)	1981-1986
• Name and type of organization providing education and training	Classical High School V. Pollione Formia (LT)
• Principal subjects/occupational skills covered by the study	Greek, Italian Literature, History, Philosophy, Latin

• Date (from– to)	1986-1992
• Name and type of organization providing education and training	University of Rome "La Sapienza"
• Principal subjects/occupational skills covered by the study	General Surgery and organ transplants. Oncology.
• Qualification achieved	Degree in Medicine and Surgery
• Degree thesis	"Ultrastructural study of human thyroid tumors"
• Grade obtained	110/110 cum laude
• Date (from – to)	1993-97
• Name and type of organization providing education and training	University of Rome Tor Vergata
• Qualification achieved	Specialization in Oncology
• Postgraduate thesis	"Biological prognostic factors in patients with breast cancer treated with primary chemotherapy"
• Grade obtained	50/50 cum laude
OTHER COURSES	
• Date (from – to)	20.11.95-24.11.95
• Name and type of organization providing education and training	Course "Differentiation and Tumors" held in Genoa at the school for Biotechnology and Experimentation in Oncology, Center for Advanced Biotechnologie
• Date (from – to)	09.02.1996-09.02.1996
• Name and type of organization providing education and training	Course of the Residential Area School of Biomedical Sciences and Oncology "Tumor markers from the laboratory to the clinic" held in Santa Margherita Ligure
• Date (from-to)	10.2002
• Name and type of organization providing education and training	BLSD at European Institute of Oncology
• Date (from-to)	21/09/2012 -17/11/2012
• Name and type of organization providing education and training	Course of Medical Writing

PERSONAL SKILLS

FIRST LANGUAGE

ITALIAN

ENGLISH - FRENCH

- Reading skills
- Writing skills
- Verbal skills

GOOD

GOOD

GOOD

SOCIAL SKILLS AND COMPETENCES

Excellent interpersonal skills with colleagues in the workplace, adaptability and flexibility. Skills and competences acquired in the course of various experiences carried out during and after the course of university studies.

ORGANIZATIONAL SKILLS AND COMPETENCES

Excellent organizational skills and ability to work independently and in team , problem-solving skills acquired during the various working experiences

TECHNICAL SKILLS AND COMPETENCES

Competence in carrying out paracentesis and thoracentesis

ARTISTIC SKILLS AND COMPETENCES

Lecture, music and travel. I have attended several courses of dance and song

Papers :

F. Nolè , E. Cocorocchio, S. Cinieri, L. Orlando, **I. Minchella**, F.Peccatori and A. Goldhirsch.
Effects of cancer therapy on reproductive function. Bullettin Suisse Du Cancer. 4:151-153, 1997

Nolè F, De Braud F, Aapro M, **Minchella I**, De Pas M, Zampino MG, Monti S, Andreoni G and Goldhirsch A.

Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: A regimen with a low subjective toxic burden. Ann Oncol, 8:865-870, 1997

M.Colleoni, F. Nole', **I. Minchella**, C. Noberasco, A. Luini, A. Orecchia, P. Veronesi, S. Zurrida, G. Viale, and A. Goldhirsch.

Pre-operative chemotherapy and radiotherapy in breast cancer. European Journal of Cancer, Vol.34, 5 : 641-645, 1998

F. Nolè, M. Colleoni, **I. Minchella**, A. Goldhirsch.

Chemioterapia adiuvante con CMF in associazione a radioterapia o Tamoxifen: sono tutti uguali i regimi CMF?. Attualità in Senologia 21: 5-9, 1998

M.Colleoni, E. Orvieto, F. Nolè, L. Orlando, **I. Minchella**, G. Viale, G. Peruzzotti, C. Robertson, C. Noberasco, V. Galimberti, V. Sacchini, P. Veronesi, S. Zurrida, R. Orecchia and A. Goldhirsch.

Prediction of Response to Primary Chemotherapy for Operable Breast Cancer. European Journal of Cancer Vol. 35, 4: 574-579, 1999.

F. Nolè, **I. Minchella**, M. Colleoni, E. Orvieto, E. Munzone, F. de Braud, G. Peruzzotti , G. Martinelli, M. G. Zampino, C. Catania, M. Pizzamiglio, P. Veronesi, S. Zurrida, V. Galimberti, A. Goldhirsch and U. Veronesi.

Primary chemotherapy in operable breast cancer with favorable prognostic factor : A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). Annals of Oncology, 10: 993-996, 1999.

Colleoni M, **Minchella I**, Mazzarol G, Nole F, Peruzzotti G, Rocca A, Viale G, Orlando L, Ferretti G, Curigliano G, Veronesi P, Intra M, Goldhirsch A.

Response to primary chemotherapy in breast cancer patients with tumor not expressing estrogen and progesterone receptors. Ann.Oncol.2000 Aug; 11(8):1057-9

L. Orlando, M. Colleoni, G. Curigliano, F. Nolè, G. Ferretti, G. Masci, G.Peruzzotti, **I. Minchella**, M. Intra, P. Veronesi, G. Viale and A. Goldhirsch.

Chemotherapy with Vinorelbine, Cisplatin and Continuous Infusion of 5-Fluorouracil in Locally Advanced Breast Cancer : A Promising Low-toxic Regimen. Anticancer Res. 21: 4135-40 (2001)

Nole F, Munzone E, Mandala M, Catania C, Orlando L, Zampino MG, **Minchella I**, Colleoni M, Peruzzotti G, Marrocco E, Goldhirsch A.

Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients : a phase II study. Ann.Oncol.2001 Jan.; 12 (1): 95-100

Curigliano G,Mandala M, **Minchella I**, Goldhirsch A. Mediastinal lymphadenopathy in a patient with breast cancer. Lancet Oncol. 2002 Mar; 3 (3) : 174.

Colleoni M, Curigliano G, **Minchella I**, Peruzzotti G, Nole F, Mazzarol G, Renne G, Orlando L, Rocca A, Veronesi P, Intra M, Viale G, Sandri MT, Severi G, Goldhirsch A

Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. Ann Oncol. 2003 Oct;14(10):1477-83.

G Curigliano ,R Rigo, M Colleoni , F de Braud , F Nolè , V Formica , L Orlando , S Cinieri R Torrisi, A Cardillo , G Perruzzotti , M Medici , R Ardito, I Minchella, A Goldhirsch
Adjuvant Therapy for Very Young Women with Breast Cancer: Response According to Biologic and Endocrine Features. Clinical Breast Cancer , Vol. 5, No. 2, 125-130, 2004.

Nolè F, Catania C, Munzone E, Rocca A, Verri E, Sanna G, Ascione G, Adamoli L, Zampino MG, I Minchella, Goldhirsch A

Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer. Clin Breast Cancer. 2006 Feb;6(6):518-24.

Sanna G, Franceschelli L., Rotmensz N, Botteri E, Adamoli L, Marenghi C, Munzone E, Cossu Rocca M, Verri E, Minchella I, Medici M, Catania C, Magni E, Goldhirsch A, Nolè F.

Brain metastases in patients with advanced breast cancer. Anticancer Res. 2007 Jul-Aug 27; (4C) : 2865-9

Catania C, Medici M, Magni E, Munzone E, Cardinale D, Adamoli L, Sanna G, Minchella I Radice D, Goldhirsch A, Nolè F

Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. Ann Oncol.2007 Sep 9

Nolè F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Verri E, Adiamoli L, Rotmensz N, Goldhirsch A., Sandri MT

Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol. 2008 May;19(5):891-7.

Lorizzo K, Fazio N, Radice D, Boselli S, Ariu L, Zampino MG, Nolè F, Magni E, Ardito R, Minchella I, Rocca A, Di Meglio G, Squadroni M, de Braud F.

Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.
Cancer Chemother Pharmacol. 2009 Jul;64(2):301-6.

Munzone E, Di Pietro A, Goldhirsch A, Minchella I, Verri E, Cossu Rocca M, Marenghi C, Curigliano G, Radice D, Adamoli L, Nolè F Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. Breast. 2010 Feb;19(1):33-7. Epub 2009 Nov 1.

Iorfida M, Bagnardi V, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Intra M, Minchella I, Veronesi P, Viale G, Goldhirsch A, Colleoni M.

Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer.

Breast. 2010 Jan 28.

Munzone E, Nolé F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, Curigliano G, Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT.

Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer. 2010 Oct 1;10(5):392-7

Catania C, De Pas T, Minchella I, De Braud F, Micheli D, Adamoli L, Spitaleri G, Noberasco C, Milani A, Zampino MG, Toffalorio F, Radice D, Goldhirsch A, Nolè F.

"Waiting and the waiting room: how do you experience them?" emotional implications and suggestions from patients with cancer. J Cancer Educ. 2011 Jun;26(2):388-94.

Aurilio G, Munzone E, Botteri E, Sciandivasci A, Adamoli L, Minchella I, Esposito A, Cullurà D, Curigliano G, Colleoni M, Goldhirsch A, Nolè F.

Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report. Breast J. 2012 Sep;18 (5):470-4

Gelao L, Criscitiello C, Fumagalli L, Locatelli M, Manunta S, Esposito A, **Minchella I**, Goldhirsch A, Curigliano G.

Tumour dormancy and clinical implications in breast cancer.

Ecancermedicalscience. 2013 May 21;7:320

Curigliano G, Criscitiello C, Esposito A, Fumagalli L, Gelao L, Locatelli M, **Minchella I**, Goldhirsch A. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium. Breast. 2013 Aug;22 Suppl 2:S 96-9

Esposito A, Bardelli A, Criscitiello C, Colombo N, Gelao L, Fumagalli L, **Minchella I**, Locatelli M, Goldhirsch A, Curigliano G.

Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities. Cancer Treat Rev. 2013 Oct 23

Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, **Minchella I**, De Placido S, Santangelo M, Viale G, Goldhirsch A, Curigliano G.

High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer.

Breast. 2014 Feb;23(1):69-75

Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, **Minchella I**, Adamoli L, Goldhirsch A, Curigliano G.

Immune approaches to the treatment of breast cancer, around the corner?

Breast Cancer Res. 2014 Feb 25;16(1):204.

Gelao L, Criscitiello C, Esposito A, De Laurentiis M, Fumagalli L, Locatelli MA, **Minchella I**, Santangelo M, De Placido S, Goldhirsch A, Curigliano G.

Dendritic cell-based vaccines: clinical applications in breast cancer.

Immunotherapy. 2014;6(3):349-60. doi: 10.2217/imt.13.169. Review.

Locatelli M, Criscitiello C, Esposito A, **Minchella I**, Goldhirsch A, Cipolla C, Curigliano G.

QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review.

Target Oncol. 2015 Mar;10(1):27-43. doi: 10.1007/s11523-014-0325-x. Epub 2014 Jun 27.

Criscitiello C, André F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, Fumagalli L, Locatelli M, **Minchella I**, Orsi F, Goldhirsch A, Curigliano G.

Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res. 2014;16(2):205. Review.

Ferrucci PF, **Minchella I**, Mosconi M, Gandini S, Verrecchia F, Cocorocchio E, Passoni C, Pari C, Testori A, Coco P, Munzone E.

Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.

Melanoma Res. 2015 Jun;25(3):239-45.

Esposito A, Criscitiello C, Gelao L, Pravettoni G, Locatelli M, **Minchella I**, Di Leo M, Liuzzi R, Milani A, Massaro M, Curigliano G.

Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.

Cancer Treat Rev. 2015 Nov;41(9):793-7. doi: 10.1016/j.ctrv.2015.09.002. Epub 2015 Sep 11. Review.

Migali C, Milano M, Trapani D, Criscitiello C, Esposito A, Locatelli M, **Minchella I**, Curigliano G. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Ther Adv Med Oncol. 2016 Sep;8(5):360-74. doi: 10.1177/1758834016658423. Epub 2016 Jul 10. Review.

Trapani D, Esposito A, Criscitiello C, Mazzarella L, Locatelli M, **Minchella I**, Minucci S, Curigliano G. Entinostat for the treatment of breast cancer.

Expert Opin Investig Drugs. 2017 Aug;26(8):965-971. doi: 10.1080/13543784.2017.1353077. Epub 2017 Jul 24.

Duso BA, Trapani D, Viale G, Criscitiello C, D'Amico P, Belli C, Mazzarella L, Locatelli M, **Minchella I**, Curigliano G.

Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer.

Expert Opin Pharmacother. 2018 Feb;19(3):299-305. doi: 10.1080/14656566.2018.1429407. Epub 2018 Jan 22.

Milan 24/12/2018